ReviewAAPS PharmSciTech2025
An Updated Perspective on Skin Disease Therapy: From Conventional Methods to Nanocarrier Innovations.
Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Photodynamic Therapy for Facial Rejuvenation Combined Amber LED and Infrared Laser Irradiation: A Pilot Study Comparing ALA and MAL.Journal of biophotonics · 2026Article
- Polymeric Nanogels for Skin Applications.Gels (Basel, Switzerland) · 2026Review
- Ultradeformable liposomal delivery of vismodegib modulates its biological activity in melanoma cells.Frontiers in medical technology · 2026Article
- Quercetin in skin burn healing: mechanisms, advanced delivery systems, and translational perspectives.Frontiers in bioengineering and biotechnology · 2026Review
- Chitosan Nanoparticles Loaded with Polyphenols for Cosmeceutical Applications: A State-of-the-Art Review.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin conditions are becoming more prevalent these days, affecting millions of people daily. Skin disorders include a wide range of conditions that can be benign or even fatal. Several pathogenic infections or inflammatory conditions have historically been the primary causes of skin diseases, causing major challenges. As demonstrated by studies, dermatological conditions are extremely severe, commonly impacting people of all ages and regions, but especially in developing nations, and imposing a heavy social and psychological burden. Conventional topical treatments for several skin diseases suffer from inefficacy, prolonged treatment duration, recurrence, and systemic side effects due to poor drug delivery. The skin's fundamental resistance to drug penetration also poses a significant hurdle. Nanocarriers are one of the most promising approaches since they address the drawbacks of conventional formulations and offer effective drug delivery via the skin. By using nanocarriers to provide continuous release and maintain a localized effect, many diseases or skin conditions can be effectively treated. This review discusses various common skin diseases, challenges associated with conventional treatments, and the impact of nanomedicine on dermatological care. Discussing the role of interleukins, this review also modulates the immune responses implicated in several skin diseases, including psoriasis and atopic dermatitis.
Indexed as
Identifiers
40775555What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.